Skip to main navigation Skip to main content Skip to footer For Medicare For Providers For Brokers For Employers Español For Individuals & Families: For Individuals & Families Medical Dental Other Supplemental Explore coverage through work How to Buy Health Insurance Types of Dental Insurance Open Enrollment vs. Special Enrollment See all topics Shop for Medicare plans Member Guide Find a Doctor Log in to myCigna
Home Knowledge Center Wellness Library Tarlatamab-dlle Injection

Tarlatamab-dlle Injection

Brand Name(s): Imdelltra®

IMPORTANT WARNING:

IMPORTANT WARNING:

Tarlatamab-dlle injection should be given only under the supervision of a doctor with experience in the use of chemotherapy medications.

Tarlatamab-dlle injection may cause a serious, life-threatening reaction known as cytokine release syndrome (CRS) that may occur during and following infusion of this medication. Tell your doctor if you have ever had a reaction to tarlatamab-dlle or any other medication. You will receive certain medications to help prevent an allergic reaction before you receive each dose of tarlatamab-dlle. If you experience any of the following symptoms during or after receiving tarlatamab-dlle, tell your doctor immediately: fever, tiredness, weakness, dizziness, headache, nausea, vomiting, chills, rash, swelling of the face, wheezing, or difficulty breathing. If you experience a severe reaction, your doctor will stop your infusion and treat the symptoms of the reaction.

Tarlatamab-dlle injection may also cause serious, life-threatening central nervous system reactions. Tell your doctor if you have or have ever had seizures, confusion, loss of balance, or trouble speaking. If you experience any of the following symptoms, tell your doctor immediately: seizures, uncontrollable shaking of a part of the body, difficulty speaking, slurred speech, loss of consciousness, difficulty falling asleep or staying asleep, headache, confusion, or loss of balance.

Your doctor or pharmacist will give you the manufacturer's patient information sheet (Medication Guide) when you begin treatment with tarlatamab-dlle and each time you refill your prescription. Read the information carefully and ask your doctor or pharmacist if you have any questions. You can also visit the Food and Drug Administration (FDA) website (https://www.fda.gov/Drugs/DrugSafety/ucm085729.htm) or the manufacturer's website to obtain the Medication Guide.

Talk to your doctor about the risk(s) of using tarlatamab-dlle injection.

WHY is this medicine prescribed?

WHY is this medicine prescribed?

Tarlatamab-dlle is used for treatment of advanced small cell lung cancer (SCLC) that has progressed on or after other treatments. Tarlatamab-dlle is in a class of medications called bispecific T-cell engager antibodies. It works by slowing or stopping the growth of cancer cells in your body.

Are there OTHER USES for this medicine?

Are there OTHER USES for this medicine?

This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

HOW should this medicine be used?

HOW should this medicine be used?

Tarlatamab-dlle comes as a powder to be mixed with a liquid and to be given intravenously (into a vein) by a doctor or a nurse at a hospital or medical clinic. Tarlatamab-dlle will be given every 7 days for 3 doses and then every 2 weeks.

Your doctor may need to delay your treatment, change your dose, or stop your treatment if you experience certain side effects. It is important for you to tell your doctor how you are feeling during your treatment with tarlatamab-dlle injection.

What SPECIAL PRECAUTIONS should I follow?

What SPECIAL PRECAUTIONS should I follow?

Before receiving tarlatamab-dlle,

  • tell your doctor and pharmacist if you are allergic to tarlatamab-dlle, any other medications, or any of the ingredients in tarlatamab-dlle injection. Ask your pharmacist or check the Medication Guide for a list of the ingredients.

  • tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take.

  • tell your doctor if you have an infection or if you have or have ever had an infection that keeps coming back. Also, tell your doctor if you have ever had radiation therapy to the brain or have received chemotherapy or have or have ever had liver disease.

  • tell your doctor if you are pregnant or plan to become pregnant. You will need to have a pregnancy test before you receive this medication. You should not become pregnant during your treatment with tarlatamab-dlle and for at least 2 months after your final dose. Talk to your doctor about types of birth control that will work for you. If you become pregnant while using tarlatamab-dlle, call your doctor. Tarlatamab-dlle may harm the fetus.

  • tell your doctor if you are breastfeeding. Do not breastfeed while receiving tarlatamab-dlle and for at least 2 months after your final dose.

  • do not have any vaccinations without talking to your doctor.

What SPECIAL DIETARY instructions should I follow?

What SPECIAL DIETARY instructions should I follow?

Unless your doctor tells you otherwise, continue your normal diet.

What SIDE EFFECTS can this medicine cause?

What SIDE EFFECTS can this medicine cause?

Tarlatamab-dlle may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

  • tiredness
  • reduced appetite
  • nausea
  • constipation
  • muscle pain
  • shortness of breath
  • cough
  • bad or metallic taste in the mouth

Some side effects can be serious. If you experience any of these symptoms or those listed in the IMPORTANT WARNING section, call your doctor immediately or get emergency medical treatment:

  • shortness of breath, trouble breathing, rash, wheezing
  • tiredness, loss of appetite, pain in the upper, right-side of the stomach, dark urine, yellowing of skin or whites of eyes
  • fever, cough, chest pain, shortness of breath, tiredness, sore throat, pain during urination, feeling unwell

Tarlatamab-dlle may cause other side effects. Call your doctor if you have any unusual problems while taking this medication.

If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online (https://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).

What OTHER INFORMATION should I know?

What OTHER INFORMATION should I know?

Keep all appointments with your doctor and the laboratory. Your doctor will order certain lab tests to check your body's response to tarlatamab-dlle.

If you miss a scheduled appointment for a tarlatamab-dlle dose, call your doctor or clinic right away to reschedule.

It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.

This information does not replace the advice of a doctor. Ignite Healthwise, LLC, disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. Learn how we develop our content.

Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Ignite Healthwise, LLC.

<cipublic-spinner variant="large"><span>Loading…</span></cipublic-spinner>

Page Footer

I want to...

Get an ID card File a claim View my claims and EOBs Check coverage under my plan See prescription drug list Find an in-network doctor, dentist, or facility Find a form Find 1095-B tax form information View the Cigna Glossary Contact Cigna

Audiences

Individuals and Families Medicare Employers Brokers Providers

Secure Member Sites

myCigna member portal Health Care Provider portal Cigna for Employers Client Resource Portal Cigna for Brokers

The Cigna Group Information

About Cigna Healthcare Company Profile Careers Newsroom Investors Suppliers The Cigna Group Third Party Administrators International Evernorth

 Cigna. All rights reserved.

Privacy Legal Product Disclosures Cigna Company Names Customer Rights Accessibility Non-Discrimination Notice Language Assistance [PDF] Report Fraud Sitemap Cookie Settings

Disclaimer

Individual and family medical and dental insurance plans are insured by Cigna Health and Life Insurance Company (CHLIC), Cigna HealthCare of Arizona, Inc., Cigna HealthCare of Illinois, Inc., Cigna HealthCare of Georgia, Inc., Cigna HealthCare of North Carolina, Inc., Cigna HealthCare of South Carolina, Inc., and Cigna HealthCare of Texas, Inc. Group health insurance and health benefit plans are insured or administered by CHLIC, Connecticut General Life Insurance Company (CGLIC), or their affiliates (see a listing of the legal entities that insure or administer group HMO, dental HMO, and other products or services in your state). Accidental Injury, Critical Illness, and Hospital Care plans or insurance policies are distributed exclusively by or through operating subsidiaries of Cigna Corporation, are administered by Cigna Health and Life Insurance Company, and are insured by either (i) Cigna Health and Life Insurance Company (Bloomfield, CT); (ii) Life Insurance Company of North America (“LINA”) (Philadelphia, PA); or (iii) New York Life Group Insurance Company of NY (“NYLGICNY”) (New York, NY), formerly known as Cigna Life Insurance Company of New York. The Cigna name, logo, and other Cigna marks are owned by Cigna Intellectual Property, Inc. LINA and NYLGICNY are not affiliates of Cigna.

All insurance policies and group benefit plans contain exclusions and limitations. For availability, costs and complete details of coverage, contact a licensed agent or Cigna sales representative. This website is not intended for residents of New Mexico.

Selecting these links will take you away from Cigna.com to another website, which may be a non-Cigna website. Cigna may not control the content or links of non-Cigna websites. Details